CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $51.81, indicating a -3.5% shift from the ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

CRISPR Therapeutics stock has slipped 20% from its 2025 high in July, and Wood took advantage of that to add more shares of ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 7.75%. Read on to learn why. Crispr Therapeutics AG has experienced a notable 7.75% increase in ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

What you need to know about Ark Invest, an active ETF firm led by Cathie Wood that invests in disruptive, high-growth tech ...